funnyangel / Shutterstock.com
The US Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) will review one of AbbVie’s patents covering its arthritis treatment drug Humira (adalimumab), following a challenge by drug maker Coherus Bioscience.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Coherus Bioscience, Patent, PTAB, Humira